Form 4/A for NDRA ENDRA Life Sciences Inc.
Accepted 2024-09-05 00:00:00 ET · period of report 2024-08-27 · accession 0001610520-24-000153 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2024-09-05 | 2024-08-27 | NDRA | UBS Group AG | Market maker, broker-dealer | P - Purchase | — | 0 | 146.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-27 | P | A | 0 | $0.00 | 146,012 | I By Subsidiary | — | — | (F1) This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group. (F2) This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024. Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares. When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares. Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary |